Drug Search Results
More Filters [+]

AXP-1275

Alternative Names: axp-1275, axp1275, axp 1275
Latest Update: 2016-02-05
Latest Update Note: Clinical Trial Update

Product Description

an oral, small-molecule inhibitor of CCR3

Mechanisms of Action: CCR3 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Axikin
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AXP-1275

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Asthma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AXP1275-201

P2

Completed

Asthma

2014-04-01

Recent News Events

Date

Type

Title